United Kingdom & Gilead Sciences

United Kingdom: One of the Western countries that slashed foreign assistance, contributing to Joint United Nations Programme on HIV/AIDS funding loss.

Gilead Sciences: Developed lenacapavir, a highly effective HIV prevention injectable; faces potential revenue impact from generic production in South Africa.

United Kingdom: Committed £21 million and deployed experts; no confirmed cases.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

United Kingdom: Reduced HIV funding as part of European cuts, contributing to the overall decline.

Gilead Sciences: Facing pressure to expand access to lenacapavir; its pricing and licensing decisions are under scrutiny.

United Kingdom: The United Kingdom has ruled out temperature checks at its airports for flights from affected regions, indicating a low perceived global risk from the Ebola outbreak, but also highlighting past ineffectiveness of such measures.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

United Kingdom: The United Kingdom>>> is one of multiple nations that have implemented travel restrictions in response to the Ebola outbreak, indicating a global concern.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

United Kingdom: The United Kingdom hosts the new co-innovation hub in London, potentially boosting its position as a center for AI and life sciences.

Gilead Sciences: Gilead Sciences is mentioned as an existing AWS customer, but this event does not directly impact it.